Oncology · Radiation TherapyTrial Updateclinicalmid-term

Trial on MRI-guided SBRT for Liver Metastases Aims to Establish Safe Dose Levels

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AstraZeneca131 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/13/2026, 6:00:18 AM

Assessment confidence: 65% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This clinical trial aims to establish safe dose levels for MRI-guided SBRT in treating liver metastases, which could significantly influence treatment protocols in oncology. The outcomes may enhance the competitive positioning of companies involved in advanced radiation therapies. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (10 high-relevance).

Strategic Assessment

Success in establishing safe dose levels may enhance treatment options and market positioning for companies involved in radiation therapy. The strongest clinical anchor is Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (ClinicalTrials.gov), patient population match (advanced). In Oncology · Radiation Therapy, 7 regulatory and 4 competitive items passed relevance filtering for radiation therapy companies.

Competitive Pressure

The most relevant competitive pressure comes from Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma (Humanexa Signals) — patient population match (advanced). Secondary pressure from MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated. This trial could provide insights into the safety and efficacy of advanced radiation techniques, impacting competitive positioning in oncology treatments.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONTRUZANT (SUPPL) (FDA). Regulatory pathway relevance (bla). Relevant agencies in corpus: FDA, MHRA. Establishing safe dose levels could facilitate regulatory approvals for new treatment protocols, thereby influencing compliance and market entry strategies.

Key Risks

Elevated medium regulatory exposure for radiation therapy companies could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on radiation therapy companies through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If successful, this trial could lead to new treatment options that may capture market share in the oncology sector, impacting revenue streams for companies involved in radiation therapy.
Oncology · Melanoma · Trial Update · This trial introduces a novel combination therapy that could enhance treatment options for patients with advanced melanoma, potentially impacting the competitive landscape for existing therapies.
Oncology · Oropharyngeal Cancer · Trial Update · This trial could provide insights into more precise radiotherapy techniques, potentially influencing treatment standards in oropharyngeal cancer.
Upside for radiation therapy companies may improve if Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Success in establishing safe dose levels may enhance treatment options and market positioning for companies involved in radiation therapy.

What Would Change This Assessment

This becomes more urgent if Monitor the trial's progress and results for potential shifts in treatment protocols and competitive dynamics in oncology.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONTRUZANT (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ENHERTU (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — HERCEPTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respir
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma
Humanexa Signalshigh relevance
Patient population match (advanced)
MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated
Humanexa Signalsmedium relevance
Moderate corpus alignment
Pridopidine Phase 3 Trial Initiated for ALS Efficacy and Safety Evaluation
Humanexa Signalsmedium relevance
Moderate corpus alignment
Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors
Humanexa Signalsmedium relevance
Moderate corpus alignment

Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
FEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

radiation therapy companies
oncology treatment protocols
clinical trial participants

Commercial impact

medium

If successful, this trial could lead to new treatment options that may capture market share in the oncology sector, impacting revenue streams for companies involved in radiation therapy.

Regulatory impact

medium

Establishing safe dose levels could facilitate regulatory approvals for new treatment protocols, thereby influencing compliance and market entry strategies.

What to watch

Monitor the trial's progress and results for potential shifts in treatment protocols and competitive dynamics in oncology.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.